UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 83

Sortiert nach

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

Annals of oncology, 2015-09, Vol.26 (9), p.1987-1993

2015

Volltextzugriff (PDF)

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

Pharmacology & therapeutics (Oxford), 2007-12, Vol.116 (3), p.496-526

2007

Volltextzugriff (PDF)

Cytochrome P450 pharmacogenetics and cancer

Oncogene, 2006-03, Vol.25 (11), p.1679-1691

2006

Volltextzugriff (PDF)

Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism

The pharmacogenomics journal, 2008-08, Vol.8 (4), p.268-277

2008

Volltextzugriff (PDF)

Pharmacogenomic biomarkers for personalized cancer treatment

Journal of internal medicine, 2015-02, Vol.277 (2), p.201-217

2015

Volltextzugriff (PDF)

Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients

Breast cancer research and treatment, 2015-01, Vol.149 (2), p.385-394

2015

Volltextzugriff (PDF)

Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma

Annals of oncology, 2013-09, Vol.24 (9), p.2409-2414

2013

Volltextzugriff (PDF)

Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity

The pharmacogenomics journal, 2011-04, Vol.11 (2), p.121-129

2011

Volltextzugriff (PDF)

Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma

The pharmacogenomics journal, 2017-01, Vol.17 (1), p.42-46

2017

Volltextzugriff (PDF)

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma

British journal of cancer, 2015-03, Vol.112 (7), p.1190-1198

2015

Volltextzugriff (PDF)

Quantitative RT-PCR Measurement of Human Cytochrome P-450s: Application to Drug Induction Studies

Archives of biochemistry and biophysics, 2000-04, Vol.376 (1), p.109-116

2000

Volltextzugriff (PDF)

High frequency and founder effect of the CYP3A420 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme

The pharmacogenomics journal, 2015-06, Vol.15 (3), p.288-292

2015

Volltextzugriff (PDF)

Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing

Lung cancer (Amsterdam, Netherlands), 2020-09, Vol.147, p.106-114

2020

Volltextzugriff (PDF)

Molecular characterisation of a common SDHB deletion in paraganglioma patients

Journal of medical genetics, 2008-04, Vol.45 (4), p.233-238

2008

Volltextzugriff (PDF)

Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment

Human genetics, 2010-01, Vol.127 (1), p.1-17

2010

Volltextzugriff (PDF)

Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy

Philosophical transactions of the Royal Society of London. Series B. Biological sciences, 2005-08, Vol.360 (1460), p.1563

2005

Volltextzugriff (PDF)

Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer

Endocrine-related cancer, 2007-09, Vol.14 (3), p.645-654

2007

Volltextzugriff (PDF)

Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy

Clinical cancer research, 2012-08, Vol.18 (16), p.4441-4448

2012

Volltextzugriff (PDF)

Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells

Xenobiotica, 2002-06, Vol.32 (6), p.505-520

2002

Volltextzugriff (PDF)

Transcriptional regulation of human CYP3A4 basal expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear factor-3 gamma

Molecular pharmacology, 2003-05, Vol.63 (5), p.1180-1189

2003

Volltextzugriff (PDF)

Oxaliplatin induced-neuropathy in digestive tumors

Critical reviews in oncology/hematology, 2014-01, Vol.89 (1), p.166-178

2014

Volltextzugriff (PDF)

Role of cytochrome P450 2C83 (CYP2C83) in paclitaxel metabolism and paclitaxel-induced neurotoxicity

Pharmacogenomics, 2015-06, Vol.16 (9), p.929-937

2015

Volltextzugriff (PDF)

Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics

Genetics in medicine, 2018-06, Vol.20 (6), p.622-629

2018

Volltextzugriff (PDF)

Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia

The pharmacogenomics journal, 2020-04, Vol.20 (2), p.179-191

2020

Volltextzugriff (PDF)

Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel--letter

Clinical cancer research, 2015-07, Vol.21 (13), p.3092-3093

2015

Volltextzugriff (PDF)

1 – 25 von 83

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(77)
Mit Volltextzugriff
(77)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(47)
Life Sciences & Biomedicine
(45)
Science & Technology
(45)
Medicin Och Hälsovetenskap
(36)
Female
(23)
Male
(16)
Middle Aged
(16)
Oncology
(16)
Aged
(15)
Genetics & Heredity
(15)
Pharmacology & Pharmacy
(15)
Adult
(14)
Cytochrome P-450 Enzyme System - Genetics
(14)
Polymorphism, Single Nucleotide
(11)
Aryl Hydrocarbon Hydroxylases - Genetics
(10)
Alleles
(9)
Animals
(9)
Polymorphism, Genetic
(9)
Aged, 80 And Over
(8)
Biochemistry & Molecular Biology
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

Cytochrome P450 pharmacogenetics and cancer

Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism

Pharmacogenomic biomarkers for personalized cancer treatment

Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients

Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma

Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity

Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma

Quantitative RT-PCR Measurement of Human Cytochrome P-450s: Application to Drug Induction Studies

High frequency and founder effect of the CYP3A420 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme

Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing

Molecular characterisation of a common SDHB deletion in paraganglioma patients

Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment

Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy

Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer

Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy

Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells

Transcriptional regulation of human CYP3A4 basal expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear factor-3 gamma

Oxaliplatin induced-neuropathy in digestive tumors

Role of cytochrome P450 2C83 (CYP2C83) in paclitaxel metabolism and paclitaxel-induced neurotoxicity

Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics

Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia

Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel--letter

Suchergebnisse filtern